Selank · 13MG

Selank is a synthetic heptapeptide consisting of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow as a synthetic analog of the natural immunomodulatory peptide tuftsin (a 4-amino-acid fragment of IgG Fc heavy chain, residues 289-292). Selank extends the tuftsin sequence with a C-terminal Pro-Gly-Pro tripeptide that confers peptidase resistance and extended plasma stability compared to natural tuftsin. The compound has been extensively investigated in Russian academic literature (Semenova, Andreeva, Myasoedov, and colleagues) for tuftsin receptor binding, GABAergic gene expression endpoints, BDNF expression in hippocampal cell research, and Th1/Th2 cytokine balance in immune cell research models. Selank is one of the most-studied Russian-origin neuropeptides and serves as the comparator compound for stabilized analogs including N-Acetyl Selank (with N-terminal acetylation for further peptidase protection). The compound is studied here primarily as a research tool for tuftsin-class peptide pharmacology and structure-activity relationship (SAR) studies of peptide tuftsin extensions.

Benefits (Research Focus)

• Tuftsin receptor pharmacology — studied as the standard tuftsin extended analog for receptor binding research

• GABAergic gene expression — investigated for transcriptomic effects on GABA-related genes in CNS cell research models

• BDNF pathway research — explored for hippocampal BDNF gene expression endpoints in rodent research models

• Th1/Th2 cytokine research — examined for cytokine profile shifts in immune cell research models

• Comparative SAR research — researched alongside N-Acetyl Selank for comparative N-terminal modification studies

What Researchers Look At

• Tuftsin receptor binding affinity and selectivity profiles

• Hippocampal BDNF gene and protein expression in rodent research models

• GABA-related gene expression and signaling pathway markers in CNS research

• Th1/Th2 cytokine balance and immune cell research endpoints

• Comparative pharmacology versus N-Acetyl Selank and other tuftsin-class research compounds

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 13 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Selank

• Synonyms: TKPRPGP; tuftsin extended analog; heptapeptide tuftsin derivative

• Class: Synthetic heptapeptide; tuftsin-class peptide; Russian-origin neuropeptide research compound

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) — 7 amino acids

• Origin: Institute of Molecular Genetics, Russian Academy of Sciences (Moscow); synthesized as a tuftsin analog with C-terminal Pro-Gly-Pro extension

• Formula / M.W.: C₃₃H₅₇N₁₁O₉, ~751.89 g/mol

• CAS: 129954-34-3

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Selank Janoshik Verification — October 3, 2025

• Selank Janoshik Verification — May 6, 2026